Related Experiment Video
Updated: Feb 9, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Initial experience of percutaneous left atrial appendage closure using the LAmbre device for thromboembolic
Nico Reinsch1,2, Ute Ruprecht1,3,2, Jochen Buchholz1
1Department of Electrophysiology, Alfried Krupp Krankenhaus.
Insights
The LAmbre device offers a new option for percutaneous left atrial appendage (LAA) closure in atrial fibrillation patients. Initial studies show successful implantation and good clinical outcomes, even in complex cases.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Atrial fibrillation (AF) poses a significant stroke risk, especially in patients ineligible for anticoagulation.
- Percutaneous left atrial appendage (LAA) closure is an established stroke prevention strategy.
- The LAmbre occluder is a novel device designed for adaptable LAA closure.
Purpose of the Study:
- To assess the feasibility and initial clinical experience of LAA occlusion using the LAmbre device.
- To evaluate the LAmbre occluder in a non-selected patient cohort.
- To demonstrate the device's adaptability in various LAA anatomies.
Main Methods:
- Implantation of the LAmbre occluder in 11 patients with nonvalvular AF.
- Follow-up assessments at 6 weeks and 6 months, including transesophageal echocardiography.
- Evaluation of procedural success and clinical outcomes.
Main Results:
- Successful LAmbre device implantation in all 11 patients.
- No deaths, strokes, systemic thromboembolism, or major bleeding occurred within 6 months.
- Minimal peridevice flow (<5mm) was noted in one patient; no device-related thrombus or effusion observed.
Conclusions:
- The LAmbre occluder is a feasible and effective novel device for LAA closure.
- It offers versatile options for physicians, particularly for challenging LAA anatomies.
- Initial experience indicates a good success rate and favorable clinical outcomes.
Aims:
Stroke due to atrial fibrillation has been associated with a high risk of disability and mortality. Percutaneous left atrial appendage (LAA) closure has been established as an alternative strategy for stroke prevention in patients not eligible for oral anticoagulation. The LAmbre is a novel occluder, specifically designed for LAA closure adaptive to various LAA anatomies. The aim of this study was to demonstrate feasibility and initial experience in a nonprescreened patient cohort for LAA occlusion using the novel LAmbre occluder.
Methods:
The device was implanted in 11 patients with nonvalvular atrial fibrillation. Follow-up included transesophageal echocardiography and an outpatient visit at 6 weeks and 6 months after implantation.
Results:
All devices were implanted successfully. Device sizes ranged from 16/22 to 22/34 mm. Patients' mean CHA2DS2-VASc and HAS-BLED scores were 3.3 ± 1.0 and 3.2 ± 1.0, respectively. Two out of 11 patients had previously been rejected for Watchman occluder implantation by reasons of too small LAA. At 6 weeks and 6 months, there were no deaths, strokes, systemic thromboembolism or severe bleeding complications. There was no device-related thrombus or pericardial effusion seen with transesophageal echocardiography. In one out of 11 patients, a minimal peridevice flow (less than 5 mm) was present at 6-week follow-up.
Conclusion:
The LAmbre occluder is a novel LAA-closure device with features that provide many options for LAA-closure to physicians, particularly in patients with challenging anatomies. From our initial experience, implantation is associated with a good success rate and clinical outcome.
Related Concept Videos
Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
Initiation of Translation
Surface Appendages of Archaea
Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...
Cancer Prevention
Some...
Angle Closure Glaucoma: Treatment

